This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



idarubicin hydrochloride (Zavedos®)


Reference No. 2607

Publication date:
20/05/2015


Appraisal information

idarubicin hydrochloride (Zavedos®) 5 mg powder for solution for injection
idarubicin hydrochloride (Zavedos®) 10 mg powder for solution for injection


Company: Pfizer Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, idarubicin hydrochloride (Zavedos®) cannot be endorsed for use within NHS Wales for first-line treatment of acute myeloid leukaemia, in combination with cytarabine, for remission induction in children.
Statement of Advice (SOA)
Download